Simultaneous targeting of CD33/CLEC12A yields the highest coverage of pediatric AML, including LSCs. (A) Frequency of AML blasts not expressing either of 2 surface molecules as a measure of AML blasts not covered by combinatorial targeting (mean ± SD). The 7 most promising target combinations are presented. (B) Frequency of AML blasts expressing both targets of 7 promising target combinations (mean ± SD). (C-G) CD45^dim cells from 21 samples (not all samples were available for this analysis for technical reasons), with the same cell count per sample, were concatenated into 1 .fcs file, and tSNE parameters were calculated using FlowJo X default settings. Consequently, 5 target combinations (CD33/CD38 in panel C, CD33/CLEC12A in panel D, CD33/EMR2 in panel E, CD33/IL3RA in panel F, and CD33/FLT3 in panel G) are illustrated. Additionally, to depict the coverage of AML LSCs, CD34 and CD38 expression patterns are depicted on the same tSNE map (H).